Atomoxetine in the treatment of children, adolescents and adults with attention deficit hyperactivity disorder

Therapy

Volumn 3, Issue 1, 2006, Pages 19-38

  Turgay, Atilla ^a  

^a SCARBOROUGH HOSPITAL   (Canada)

Author keywords

Atomoxetine; Attention deficit hyperactivity disorder; Selective norepinephrine reuptake inhibitor; Strattera

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; AMFEBUTAMONE; AMPHETAMINE; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ATOMOXETINE; CLONIDINE; DESIPRAMINE; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; DX SPANSULE; FLUOXETINE; GUANFACINE; IMIPRAMINE; METHYLIN ER; METHYLPHENIDATE; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; PLACEBO; PSYCHOSTIMULANT AGENT; RISPERIDONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; WELBUTRIN;

ADOLESCENT; ADULT; ANOREXIA; ANXIETY; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; BEHAVIOR THERAPY; BODY WEIGHT DISORDER; CANADA; CARDIOVASCULAR DISEASE; CHILD; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; DEPRESSION; DISEASE EXACERBATION; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG ABUSE; DRUG ACTIVITY; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FAMILY RELATION; FATIGUE; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART PALPITATION; HUMAN; HUMAN RELATION; HYPERACTIVITY; IMPULSIVENESS; INSOMNIA; LIVER INJURY; MICTURITION DISORDER; MOOD DISORDER; MYDRIASIS; NAUSEA; NERVOUSNESS; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; QT PROLONGATION; SELF ESTEEM; SEXUAL DYSFUNCTION; SLEEP DISORDER; SOMNOLENCE; STOMACH PAIN; SUICIDAL IDEATION; TIC; UNITED STATES; URINE RETENTION; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

EID: 33646204399     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.1586/14750708.3.1.19     Document Type: Article

References (86)

1. Corman LS, Fedutes BA, Culley CM. Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder. Am. J. Health-Syst. Pharm. 61, 2391-2399 (2004).
2. American Academy of Pediatrics, Committee on Quality Improvement and Subcommittee on Attention Deficit/Hyperactivity Disorder. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics 105, 1158-1170 (2000).
3. Biederman J, Farone VF. Attention-deficit hyperactivity disorder. Lancet 366, 237-248 (2005).
4. Hechtman L. Assessment and diagnosis of attention-deficit/hyperactivity disorder. Child Adolesc. Psychiatr. Clin. North Am. 9, 481-498 (2000).
5. Klein RG, Mannuzza S. The long-term outcome of the attention-deficit disorder/hyperkinetic syndrome. In: Attention Deficit Disorder: Clinical and Basic Research. Sagvolden T, Archer T (Eds). Lawrence Erlbaum Associates, NJ, USA, 71-91 (1989).
6. Thorley G. Review of follow-up and follow-back studies of childhood hyperactivity. Psychol. Bull. 96, 116-132 (1984).
7. Weiss G, Hechtman LT. Hyperactive Children Grown Up (2nd Edition). Guilford Press, NY, USA (1993).
8. DiScala C, Lescohier I, Barthel M, Li G. Injuries to children with attention deficit hyperactivity disorder. Pediatrics 102, 1415-1421 (1998).
9. Biederman J, Monuteaux M, Seidman L et al. Impact of executive function deficits and ADHD on academic outcomes in children. J. Consult. Clin. Psychol. 72, 757-766 (2004).
10. Cox DJ, Humphrey JW, Merkel RL, Penberthy JK, Kovatchev B. Controlled-release methylphenidate improves attention during on-road driving by adolescents with attention-deficit/hyperactivity disorder. J. Am. Board Fam. Pract. 17, 235-239 (2004).
11. Steinhausen HC, Drechsler R, Foldenyi M, Imhof K, Brandeis D. Clinical course of attention-deficit/hyperactivity disorder from childhood toward early adolescence. J. Am. Acad. Child. Adolesc. Psychiatry 42, 1085-1092 (2003).
12. Abikoff H, Hechtman L, Klein RG et al. Social functioning in children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. J. Am. Acad. Child. Adolesc. Psychiatry 43, 820-829 (2004).
13. Greene RW, Biederman J, Faraone SV et al. Social impairment in girls with ADHD: patterns, gender comparisons, and correlates. J. Am. Acad. Child Adolesc. Psychiatry 40, 704-710 (2001).
14. Turgay A, Ansari R, Schwartz M et al. (2005). Comorbidity differences in ADHD throughout the life cycle. Presented at: Scientific and Clinical Report Section 4 - ADHD at the American Psychiatric Association Annual Scientific Meeting, May 21-26, GA, USA 66-67 (2005).
15. Faraone SV, Doyle AE. The nature and heritability of attention-deficit/ hyperactivity disorder. Child Adolesc. Psychiatr. Clin. North Am. 10, 299-316 (2001).
16. Heiligenstein JH, Spencer TJ, Biederman J et al. Tomoxetine hydrochloride, a novel noradrenergic enhancer for the treatment of pediatric and adult Attention Deficit Hyperactivity Disorder. Presented at: The American Colleague of Neuropsychopharmacology (ACNP) Annual Meeting, December 10-14, San Juan, Peurto Rico (2000).
17. MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch. Gen. Psychiatry 56, 1073-1086 (1999).
18. Greenhill L, Swanson JM, Vitiello B et al. Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. J. Am. Acad. Child Adolesc. Psychiatry. 40, 180-187 (2001).
19. Stein MA. Methylphenidate dosing: twice daily versus three times daily. Pediatrics 98, 748-756 (1996).
20. Turgay A. Diagnosing and treating ADHD in adults. Canadian J. CME February, 182-190 (2001).
21. Greenhill L. Attention deficit hyperactivity disorder: the stimulants. Child. Adolesc. Psychiatric Clin. North Amer. 4, 123-168 (1995).
22. Plizka SR. Nonstimulant treatment of attention deficit hyperactivity disorder. CNS Spectrums 8, 253-258 (2003).
23. Kratochvil CJ, Vaughan BS, Daughton JM et al. Atomoxetine in the treatment of attention deficit hyperactivity disorder. Expert Rev. Neurother. 4, 601-711 (2004).
24. Canadian ADHD Resource Alliance. Canadian ADHD Practice Guidelines. Prepared by a Guidelines Committee chaired by Jain Umesh and the members were Hechtman L, Mutch C, Quinn D, Sacks D, Turgay A, Weis M, Yaramko J. Canadian ADD Resource Alliance (2005).
25. Wender PH, Reimherr FW. Bupropion treatment of attention-deficit hyperactivity disorder in adults. Am. J. Psychiatry 147, 1018-1020 (1990).
26. Higgins ES. A comparative analysis of antidepressants and stimulants for the treatment of adults with attention-deficit hyperactivity disorder. J. Fam. Pract. 48, 15-20 (1999).
27. Spencer T, Biederman J, Wilens T et al. Pharmacotherapy of attention deficit hyperactivity disorder across life cycle. J. Am. Acad. Child. Adoles. Psychiatry 35, 409-462 (1996).
28. Wilens TE, Spencer TJ, Biederman J et al. A controlled clinical trial of buproprione for attention deficit hyperactivity disorder in adults. Am. J. Psychiatry 158, 282-288 (2001).
29. Bymaster FP, Katner JS, Nelson DL et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism of efficay in attention deficit/ hyperactivity disorder. Neuropsychopharmacology 27, 699-711 (2002).
30. Witcher JW, Long A, Smith B et al. Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder. J. Child. Adolesc. Psychopharmacol. 13, 53-63 (2003).
31. Chalon SA, Desager JP, Desante KA et al. Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites. Clin. Pharmacol. Ther. 73, 178-191 (2003).
32. Michelson D, Allen J, Busner J et al. Once-daily atomoxetine treatment for children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Am. J. Psychiatry. 159, 1896-1901 (2002).
33. Witcher JW, Long A, Smith B et al. Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperacticity disorder. J. Child. Adolesc. Psychopharmacol. 13, 5363 (2003).
34. Farid NA, Bergstrom RF, Ziege EA et al. Single-dose and steady-state pharmacokinetics of tomoxetine in normal subjects. J. Clin. Pharmacol. 25, 296-301 (1985).
35. Strattera® (atomoxetine hydrochloride). package insert. Eli Lily and Co., IN, USA (2002).
36. Ring BJ, Gillespie JS, Eckstein JA et al. Identification of the human cytochromes P.450 responsible for atomoxetine metabolism. Drug. Metab. Dispos. 30, 319-323 (2003).
37. Sauer JM, Pensler GD, Mattiuz EL et al. Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism. Drug. Metab. Dispos. 31, 98-107, (2003).
38. Guengerich FP. Human cyctochorome P450 enzymes. In: Cytochorome P450: Structure, Mechanism, and Biochemistry (2nd Edition). Ornitz de Montellano PR (Ed.). Plenum Press, NY, USA (1995).
39. Michelson D, Faries D, Wernicke J et al. Atomoxetine in the treatment of children and adolescents with attention deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 108(5) e83 (2001).
40. Michelson D, Adler L, Spencer T et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol. Psychiatry 53, 112-120 (2003).
41. Heiligenstein JH, Spencer TJ, Faries DE, Biederman J, Kratochvil C, Conners CK. Tomoxetine, Methylphenidate, placebo: comparison of treatment effects in children with ADHD. Presented at: The American Academy of Child and Adolescent Psychiatry Annual Meeting, October, DC, USA (2000).
42. Kelsey DK, Sumner CR, Casat CD. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behaviour: a double-blind, placebo-controlled trial. Pediatrics 114(1) e1-e8 (2004).
43. Spencer T, Biederman J, Wilens T et al. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Amer. J. Psychiatry 155, 693-695 (1998).
44. Banaschewski T. Non-stimulant medications in the treatment of ADHD. Eur. Chil. Adolesc. Psychiatry (Suppl.1) 13, 102-116 (2004).
45. Newcorn J. Efficacy trials of atomoxetine for ADHD in children, adolescents and adults. Presented at: The American Academy of Child and Adolescent Psychiatry 49th Annual Meeting, October 22-27, CA, USA (2002).
46. Perwien AR, Faries D, Kratochvil C. Long-term effects of atomoxetine on health related quality of life. Presented at: The American Academy of Child and Adolescent Psychiatry Annual Meeting, FL, USA (2003).
47. Kratochvil C, Heiligenstein JH, Dittmann R et al. Atomoxetine and Methylphenidate treatment in ADHD children: a prospective, randomized, open-label trial. J. Am. Acad. Child. Adolesc. Psychiatry 41(7), 776-784 (2001).
48. Swanson J, Gupta S, Guinta D et al. Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children. Clin. Pharmacol. Ther. 66, 295-305 (1999).
49. Kaufman J, Birmaher B, Brent D, Rao U, Ryan N. Kiddie-Sads-Present and Lifetime Version (K-SADS-PL). Version 1.0. Department of Psychiatry, University of Pittsburgh School of Medicine, PA, USA (1996).
50. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R. ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretations. The Guilford Press, NY, USA (1998).
51. Faries DE, Yalcin I, Harder D and Heiligenstein JH. Validation of the ADHD Rating Scale as a clinician anministered and scored instrument. J. Att. Dis. 5, 107-115 (2001).
52. Connors CK. Connors' Rating Scales-Revised: Technical Manual. Multi-Health Systems, NY, USA (1997).
53. Connors CK, Parker JDA, Citarenios G et al. The Revised Connors' Parent Rating Scale (CPRS-R): factor structure, reliability, and criterion validity. J. Abnorm. Child. Psychol. 26, 257-268 (1997).
54. Connors CK. Connors' Rating Scales-Revised. In: Handbook of Psychiatric Measures. American Psychiatric Association, DC, USA, 329-332 (2000).
55. Poznanski EO, Mokros HB. Children's Depression Rating Scale (CDRS-R) Revised (2nd Edition). Western Psychological Services, CA, USA (1999).
56. Landgraf JM, Maunsell E, Speechley KN et al. Canadian-French, German and UK versions of the Child Health Questionnaire: methodology and preliminary item scaling results. Qual. Life Res. 7, 433-445 (1998).
57. Allen AJ, Spencer T, Heiligenstein J et al. Safety and efficacy of atomoxetine for ADHD in two double-blind, placebo controlled trials. Presented at: The Society of Biological Psychiatry, May 3-5, CA, USA (2001).
58. Kratochvil CJ, Wernicke JF, Michelson D et al. Long-term safety of atomoxetine in the treatment of ADHD. Presented at: American Academy of Child and Adolescent Psychiatry Meeting, October 23-28, HI, USA (2001).
59. Spencer T, Biederman J, Heiligenstein J et al. An open-label, dose-ranging study of atomoxetine in children with Attention Deficity Hyperactivity Disorder. J. Child. Adoles. Psychopharmacol. 11(3), 251-265 (2001).
60. Kratochvil CJ, Heiligenstein JH, Dittmann et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J. Am. Acad. Child. Adolesc. Psychiatry 41, 776-789 (2002).
61. Michelson D, Buitelaar JK, Danckaerts M et al. Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo controlled study. J. Amer. Acad. Child. Adolesc. Psychiatry 43, 896-904 (2004).
62. Kratochvil CJ, Newcorn JH, Arnold LE et al. Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J. Am. Acad. Child. Adolesc. Psychiatry 44, 915-924 (2005).
63. Dunn DW, Turgay AT, Weiss M et al. Use of plasma concentration to guide atomoxetine doses in ADHD patients. New Research Presented at: The American Psychiatric Association Annual Scientific Meeting, May 21-26, GA, USA (2005).
64. Schachter HM, Pham B, King J. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit hyperactivity disorder in children and adolescents? A meta-analysis. CMAJ 165, 1475-1488 (2001).
65. Kratochvil CJ, Vaughan BS, Harrington MJ, Burke W. Atomoxetine a selective noradrenalin reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder. Expert Opin. Pharmacother. 4, 1165-1174 (2003).
66. Newcorn J, Michelson D, Spencer T et al. Atomoxetine treatment in children/adolescent ADHD with comorbid oppositional defiant disorder. Presented at: ESCAP, 8-10 April, Paris, France (2003).
67. McCracken FT, Sallee FR, Leonard HL et al. Improvement of ADHD by atomoxetine in children with tic disorders. Presented at: The Amarican Academy of Child and Adolescescent Psychiatry Annual Meeting, FL, USA (2003).
68. Coffey B, Kelsey D, Feldman P et al. Atomoxetine treatment in children with ADHD and comorbid tic disorders. Presented at: The American Psychiatric Association Annual Scientific Meeting, May 1-6, NY, USA (2004).
69. Sutton V, Sangal R, Owens J et al. Effects of atomoxetine and methylphenidate on sleep in children with ADHD. Presented at: The Annual Scientific Meeting of the American Psychiatric Association, May 1-6, NY, USA (2004).
70. Reimherr FW, Strong RE, Hedges DW et al. Emotional dysregulation in ADHD and response to atomoxetine. Presented at: The American Psychiatric Association Annual Scientific Meeting, May 1-6, NY, USA (2004).
71. Faries DE, Perwien AR, Kelsey DK et al. Effects of atomoxetine on the quality of life of children with ADHD. Presented at: The American Psychiatric Association Annual Scientific Meeting, May 1-6, NY, USA (2004).
72. Strattera® Canadian Product Monograph. Eli Lily, Canada (2004).
73. Heil SH, Holmes HW, Bickel WK et al. Comparison of the subjective, placebo, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Biol. Psychiatry 67, 149-156 (2002).
74. Belle DJ, Ernest CS, Sauer JM, Smith BP, Thomasson HR, Witcher JW. Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics. J. Clin. Pharmacol. 42, 1219-1227 (2002).
75. Wernicke JF, Faries D, Girod D et al. Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Safety 26(10), 729-740 (2003).
76. Wernicke JE, Kratochvil CJ. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J. Clin. Psychiatry 63(Suppl.12) 50-55 (2002).
77. Turgay A, Zafar M, Rizkallah and OCD Study Group. Comorbidity, gender and age relations in child and adolescent OCD. American Psychiatric Association Annual Meeting New Research 112 (2001) (Abstract).
78. Turgay A, Tonga L, Ansari R and ADHD Study Group. ADHD comorbidity: age and gender differences. American Psychiatric Association Annual Meeting Proceedings Summary 31 (2001).
79. Freeman AD, Fast DK, Burd L et al. An International perspective on Tourette's syndrome: selected findings from 3500 individuals in 22 countries. Dev. Med. Child Neurol. 42, 436-447 (2000).
80. Turgay A, Snyder R, Fisman S et al. Risperidone versus placebo in severe behavioral disturbances in children with suboptimal IQ. Biol. Psychiatry 49(Suppl.), 208 (2001).
81. Turgay A, Aman M, Binder C, Snyder R, Schulz M and Conduct Disorder Study Group. Risperidone in children with oppositional defiant disorder, conduct disorder, Subaverage IQ and comorbid ADHD. Presented at: American Academy of Child and Adolescent Psychiatry Annual Meeting October 23-28, HI, USA, 127 (2001).
82. Turgay A, Binder C, Snyder R, Fisman S. Long term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subavarage IQs. Pediatrics 100(3), e34 (2002).
83. Snyder R, Turgay A, Aman M, Binder C, Fisman S, Carroll A and risperidone study group. Effects of risperidone on conduct and disruptive behavior disorders in children with subavarage IQs. J. Amer. Acad. Child. Adolesc. Psychiatry 41(9), 1026-1036 (2002).
84. Shea S, Turgay A, Jones S et al. Risperidone in the treatment of behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 114, 634-641 (2004).
85. Turgay A. Aggression and disruptive behavior disorders in children and adolescents. Expert Rev. Neurother. 4(4), 623-632 (2004).
86. Aman MG, Binder C, Turgay A. Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. J. Child. Adolesc. Psychopharmacol. 14(2), 243-54 (2004).